Association of hospital admission and forced vital capacity endpoints with survival in patients with idiopathic pulmonary fibrosis: Analysis of a pooled cohort from three clinical trials

The Lancet Respiratory Medicine

Volumn 3, Issue 5, 2015, Pages 388-396

  Durheim, Michael T ^a,b   Collard, Harold R ^c   Roberts, Rhonda S ^a   Brown, Kevin K ^d,e   Flaherty, Kevin R ^f   King, Talmadge E ^c   Palmer, Scott M ^a,b   Raghu, Ganesh ^g   Snyder, Laurie D ^a,b   Anstrom, Kevin J ^a,b   Martinez, Fernando J ^f,h  

^a DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^b DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d DEPARTMENT OF MEDICINE   (United States)

^e UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^f UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^g UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^h WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; AZATHIOPRINE; PLACEBO; PREDNISONE; SILDENAFIL; WARFARIN;

ADULT; AGED; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE COURSE; DISEASE EXACERBATION; FEMALE; FOLLOW UP; FORCED VITAL CAPACITY; HOSPITAL ADMISSION; HUMAN; INCIDENCE; LUNG FIBROSIS; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTICENTER STUDY (TOPIC); OXYGEN SATURATION; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK ASSESSMENT; SURVIVAL PREDICTION; CLINICAL TRIAL; EPIDEMIOLOGY; FIBROSING ALVEOLITIS; HOSPITALIZATION; MIDDLE AGED; MULTICENTER STUDY; PATHOPHYSIOLOGY; PHYSIOLOGY; RISK; STATISTICS AND NUMERICAL DATA; SURVIVAL ANALYSIS; UNITED STATES; VITAL CAPACITY;

AGED; COHORT STUDIES; FEMALE; HOSPITALIZATION; HUMANS; IDIOPATHIC PULMONARY FIBROSIS; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; RISK; SURVIVAL ANALYSIS; UNITED STATES; VITAL CAPACITY;

EID: 84929024418     PISSN: 22132600     EISSN: 22132619     Source Type: Journal    
DOI: 10.1016/S2213-2600(15)00093-4     Document Type: Article

References (26)

1. Raghu G, Collard HR, Egan JJ, et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis-evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 2011, 183:788-824.
2. King TE, Bradford WZ, Castro-Bernardini S, et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med 2014, 370:2083-2092.
3. Richeldi L, du Bois RM, Raghu G, et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med 2014, 370:2071-2082.
4. Collard HR, Yow E, Richeldi L, Anstrom KJ, Glazer C Suspected acute exacerbation of idiopathic pulmonary fibrosis as an outcome measure in clinical trials. Respir Res 2013, 14:73. for the IPFnet investigators.
5. du Bois RM Strategies for treating idiopathic pulmonary fibrosis. Nat Rev Drug Discov 2010, 9:129-140.
6. King TE, Albera C, Bradford WZ, et al. All-cause mortality rate in patients with idiopathic pulmonary fibrosis: implications for the design and execution of clinical trials. Am J Respir Crit Care Med 2014, 189:825-831.
7. King TE, Safrin S, Starko KM, et al. Analyses of efficacy end points in a controlled trial of interferon-γ1b for idiopathic pulmonary fibrosis. Chest 2005, 127:171-177.
8. Raghu G, Collard HR, Anstrom KJ, et al. Idiopathic pulmonary fibrosis: clinically meaningful primary endpoints in phase 3 clinical trials. Am J Respir Crit Care Med 2012, 185:1044-1048.
9. Collard HR, Brown KK, Martinez FJ, Raghu G, Roberts RS, Anstrom KJ Study design implications of death and hospitalization as endpoints in idiopathic pulmonary fibrosis. Chest 2014, 146:1256-1262. for the IPFnet investigators.
10. Martinez FJ, de Andrade JA, Anstrom KJ, King TE, Raghu G Randomized trial of acetylcysteine in idiopathic pulmonary fibrosis. N Engl J Med 2014, 370:2093-2101. for the Idiopathic Pulmonary Fibrosis Clinical Research Network.
11. Collard HR, King TE, Bartelson BB, Vourlekis JS, Schwarz MI, Brown KK Changes in clinical and physiologic variables predict survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2003, 168:538-542.
12. du Bois RM, Weycker D, Albera C, et al. Forced vital capacity in patients with idiopathic pulmonary fibrosis: test properties and minimal clinically important difference. Am J Respir Crit Care Med 2011, 184:1382-1389.
13. Flaherty KR, Mumford JA, Murray S, et al. Prognostic implications of physiologic and radiographic changes in idiopathic interstitial pneumonia. Am J Respir Crit Care Med 2003, 168:543-548.
14. Martinez FJ, Safrin S, Weycker D, et al. The clinical course of patients with idiopathic pulmonary fibrosis. Ann Intern Med 2005, 142:963-967.
15. Navaratnam V, Fogarty AW, Glendening R, McKeever T, Hubbard RB The increasing secondary care burden of idiopathic pulmonary fibrosis: hospital admission trends in England from 1998 to 2010. Chest 2013, 143:1078-1084.
16. du Bois RM, Weycker D, Albera C, et al. Ascertainment of individual risk of mortality for patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2011, 184:459-466.
17. Raghu G, Behr J, Brown KK, et al. Treatment of idiopathic pulmonary fibrosis with ambrisentan: a parallel, randomized trial. Ann Intern Med 2013, 158:641-649.
18. Noth I, Anstrom KJ, Calvert SB, et al. A placebo-controlled randomized trial of warfarin in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2012, 186:88-95. for the Idiopathic Pulmonary Fibrosis Clinical Research Network (IPFnet).
19. Brown AW, Fischer CP, Shlobin OA, et al. Outcomes after hospitalization in idiopathic pulmonary fibrosis: a cohort study. Chest 2015, 147:173-179.
20. Zisman DA, Schwarz M, Anstrom KJ, Collard HR, Flaherty KR, Hunninghake GW A controlled trial of sildenafil in advanced idiopathic pulmonary fibrosis. N Engl J Med 2010, 363:620-628. for the Idiopathic Pulmonary Fibrosis Clinical Research Network.
21. Idiopathic pulmonary fibrosis: diagnosis and treatment-international consensus statement. Am J Respir Crit Care Med 2000, 161:646-664. American Thoracic Society, European Respiratory SocietyEuropean Respiratory Society.
22. Dafni U Landmark analysis at the 25-year landmark point. Circ Cardiovasc Qual Outcomes 2011, 4:363-371.
23. Ley B, Ryerson CJ, Vittinghoff E, et al. A multidimensional index and staging system for idiopathic pulmonary fibrosis. Ann Intern Med 2012, 156:684-691.
24. Kim ES, Choi SM, Lee J, et al. Validation of the GAP score in Korean patients with idiopathic pulmonary fibrosis. Chest 2015, 147:430-437.
25. Prentice RL Surrogate endpoints in clinical trials: definition and operational criteria. Stat Med 1989, 8:431-440.
26. Wells AU, Desai SR, Rubens MB, et al. Idiopathic pulmonary fibrosis: a composite physiologic index derived from disease extent observed by computed tomography. Am J Respir Crit Care Med 2003, 167:962-969.